Skip to main
KALV
KALV logo

KalVista Pharma (KALV) Stock Forecast & Price Target

KalVista Pharma (KALV) Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

KalVista Pharmaceuticals Inc. is poised for a strong market entry with its FDA-approved product, sebetralstat, which offers a highly effective oral solution for treating acute attacks of hereditary angioedema (HAE), indicating a potential shift in patient treatment paradigms. Insights from allergists and immunologists suggest a favorable reception, with two-thirds of surveyed doctors believing that patients would be more inclined to use an oral medication, supporting a conservative projection of approximately $400 million in worldwide peak sales. The company’s robust clinical data and the anticipated positive reception of sebetralstat ahead of its June 17 PDUFA, coupled with its promising performance in treating adolescents, further establish a strong foundation for future revenue growth and market capture.

Bears say

KalVista Pharmaceuticals Inc. reported a significant net loss of $44.3 million, equating to $0.92 per share for the third quarter of FY3Q25, underscoring ongoing financial challenges as the company is likely to incur losses through sebetralstat’s early launch phase. Furthermore, if sebetralstat does not perform as anticipated, the company’s pipeline lacks sufficient developmental candidates to drive future growth, which poses a substantial risk to its operational continuity and financial stability. Additionally, the inherent regulatory uncertainties surrounding FDA approval and potential market acceptance of its oral therapies, particularly for acute treatments, further exacerbate the risks associated with its business model.

KalVista Pharma (KALV) has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of KalVista Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About KalVista Pharma (KALV) Forecast

Analysts have given KalVista Pharma (KALV) a Strong Buy based on their latest research and market trends.

According to 14 analysts, KalVista Pharma (KALV) has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

KalVista Pharma (KALV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.